| Revision as of 19:56, 23 December 2024 editInnerstream (talk | contribs)Autopatrolled, Extended confirmed users4,049 edits new page | Revision as of 19:59, 23 December 2024 edit undoCitation bot (talk | contribs)Bots5,420,661 edits Add: page, display-authors, pmid, pages, issue, volume, journal, date, title, authors 1-30. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_webformNext edit → | ||
| Line 58: | Line 58: | ||
| }} | }} | ||
| '''Golidocitinib''' is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory ].<ref>{{Cite journal | doi = 10.1007/s40265-024-02089-2 }}</ref> | '''Golidocitinib''' is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory ].<ref>{{Cite journal | doi = 10.1007/s40265-024-02089-2 | title = Golidocitinib: First Approval | date = 2024 | last1 = Keam | first1 = Susan J. | journal = Drugs | volume = 84 | issue = 10 | pages = 1319–1324 | pmid = 39298087 }}</ref> | ||
| Golidocitinib is classified as a ].<ref>{{Cite journal | doi = 10.1016/S1470-2045(23)00589-2 | title = Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): A single-arm, multinational, phase 2 study | date = 2024 | last1 = Song | first1 = Yuqin | last2 = Malpica | first2 = Luis | last3 = Cai | first3 = Qingqing | last4 = Zhao | first4 = Weili | last5 = Zhou | first5 = Keshu | last6 = Wu | first6 = Jianqiu | last7 = Zhang | first7 = Huilai | last8 = Mehta-Shah | first8 = Neha | last9 = Ding | first9 = Kaiyang | last10 = Liu | first10 = Yao | last11 = Li | first11 = Zengjun | last12 = Zhang | first12 = Liling | last13 = Zheng | first13 = Meifang | last14 = Jin | first14 = Jie | last15 = Yang | first15 = Haiyan | last16 = Shuang | first16 = Yuerong | last17 = Yoon | first17 = Dok Hyun | last18 = Gao | first18 = Sujun | last19 = Li | first19 = Wenyu | last20 = Zhai | first20 = Zhimin | last21 = Zou | first21 = Liqun | last22 = Xi | first22 = Yaming | last23 = Koh | first23 = Youngil | last24 = Li | first24 = Fei | last25 = Prince | first25 = Miles | last26 = Zhou | first26 = Hui | last27 = Lin | first27 = Lie | last28 = Liu | first28 = Hui | last29 = Allen | first29 = Pamela | last30 = Roncolato | first30 = Fernando | journal = The Lancet Oncology | volume = 25 | issue = 1 | pages = 117–125 | pmid = 38092009 | display-authors = 1 }}</ref><ref>{{Cite journal | doi = 10.1182/blood-2024-211891 | title = Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26) | date = 2024 | last1 = Jin | first1 = Jie | last2 = Zhang | first2 = Liling | last3 = Zou | first3 = Liqun | last4 = Li | first4 = Zengjun | last5 = Wu | first5 = Huijing | last6 = Zhou | first6 = Keshu | last7 = Qiu | first7 = Lihua | last8 = Su | first8 = Liping | last9 = Ding | first9 = Kaiyang | last10 = Zhou | first10 = Hui | last11 = Yu | first11 = Li | last12 = Li | first12 = Fei | last13 = Xiao | first13 = Qing | last14 = Li | first14 = Wenyu | last15 = Lin | first15 = Lie | last16 = Wang | first16 = Erhua | last17 = Chen | first17 = Lijia | last18 = Cai | first18 = Qingqing | journal = Blood | volume = 144 | page = 6368 }}</ref> | |||
| Golidocitinib is classified as a ].<ref>{{Cite journal | doi = 10.1016/S1470-2045(23)00589-2 }}</ref><ref>{{Cite journal | doi = 10.1182/blood-2024-211891 }}</ref> | |||
Revision as of 19:59, 23 December 2024
Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Trade names | 高瑞哲 |
| Other names | AZD-4205, AZD4205, JAK1-IN-3 |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H31N9O2 |
| Molar mass | 489.584 g·mol |
Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Golidocitinib is classified as a Janus kinase inhibitor.
References
- Keam, Susan J. (2024). "Golidocitinib: First Approval". Drugs. 84 (10): 1319–1324. doi:10.1007/s40265-024-02089-2. PMID 39298087.
- Song, Yuqin; et al. (2024). "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): A single-arm, multinational, phase 2 study". The Lancet Oncology. 25 (1): 117–125. doi:10.1016/S1470-2045(23)00589-2. PMID 38092009.
- Jin, Jie; Zhang, Liling; Zou, Liqun; Li, Zengjun; Wu, Huijing; Zhou, Keshu; Qiu, Lihua; Su, Liping; Ding, Kaiyang; Zhou, Hui; Yu, Li; Li, Fei; Xiao, Qing; Li, Wenyu; Lin, Lie; Wang, Erhua; Chen, Lijia; Cai, Qingqing (2024). "Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)". Blood. 144: 6368. doi:10.1182/blood-2024-211891.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |